Sperm-associated antigen 9 is associated with tumor growth, migration, and invasion in renal cell carcinoma.

  title={Sperm-associated antigen 9 is associated with tumor growth, migration, and invasion in renal cell carcinoma.},
  author={Manoj Garg and Deepika Kanojia and Aashima Khosla and Namrata Dudha and Satish Sati and Dipak Chaurasiya and Nirmala Jagadish and Amlesh Seth and Rajive Kumar and Samir Gupta and Anju Gupta and Nirmal K. Lohiya and Anil Suri},
  journal={Cancer research},
  volume={68 20},
Renal cell carcinoma (RCC) represents one of the most resistant tumors to radiation and chemotherapy. Current therapies for RCC patients are inefficient due to the lack of diagnostic and therapeutic markers. Our recent studies have suggested an association of sperm-associated antigen 9 (SPAG9) with ovarian carcinomas. In the present study, we investigated the clinical relevance of SPAG9 in RCC patients. RT-PCR analysis showed expression of SPAG9 transcript in RCC tissues and RCC cell lines. In… 

Figures and Tables from this paper

Sperm associated antigen 9 (SPAG9) a promising therapeutic target of ovarian carcinoma

In vivo ovarian cancer xenograft studies showed that ablation of SPAG9 resulted in significant reduction in tumor growth, and in vitro assays revealed therapeutic potential of S PAG9 in ovarian cancer.

Sperm-associated antigen 9 is upregulated in hepatocellular carcinoma tissue and enhances QGY cell proliferation and invasion in vitro.

The results of the present study suggested that SPAG9 was upregulated in HCC and may serve an important function in cancer cell proliferation, differentiation and invasion.

Sperm Associated Antigen 9 Plays an Important Role in Bladder Transitional Cell Carcinoma

The data in clinical specimens indicated that SPAG9 is potential biomarker and therapeutic target for bladder TCC, and gene silencing resulted in reduction in cellular growth, and migration and invasion ability of cancer cells in vitro.

Ror2, a Developmentally Regulated Kinase, Is Associated With Tumor Growth, Apoptosis, Migration, and Invasion in Renal Cell Carcinoma.

Analysis of receptor tyrosine kinase-like orphan receptor 2 (Ror2), a new tumor-associated kinase, in RCC primary tumors and cell lines suggests a novel pathway of tumor-promoting activity by Ror2 within renal carcinomas, with significant implications for unraveling the tumorigenesis of RCC.

SPAG9 expression is increased in human prostate cancer and promotes cell motility, invasion and angiogenesis in vitro.

Tissue microarray and immunohistochemistry data indicate that SPAG9 expression is significantly increased in PCa and it may be involved in the process of prostate cancer cell motility, migration and angiogenesis.

Overexpression of SPAG9 correlates with poor prognosis and tumor progression in hepatocellular carcinoma

SPAG9 is overexpressed in human HCC and serves as a prognostic marker that contributes to cancer cell growth through regulation of cyclin proteins and could increase cell apoptosis.

Sperm-associated antigen 9: a novel diagnostic marker for thyroid cancer.

Findings support a potential role for SPAG9 as diagnostic biomarker as well as a possible therapeutic target in thyroid cancer treatment, and small interfering RNA-mediated knockdown of SPAg9 expression in thyroidcancer cell significantly reduced cellular growth and colony formation.

SPAG9 promotes prostate cancer growth and metastasis

In conclusion, this is the first study to provide evidence that SPAG9 promotes bone metastasis of prostate cancer, and SPAg9 is a promising target to prevent or treat bone metastases of prostatecancer.

SPAG 9 controls the cell motility , invasion and angiogenesis of human osteosarcoma cells

The results of the present study indicated that SPAG9 may be an important regulator in osteosarcoma and may be involved in metastasis, and may also be a promising target for the treatment of metastatic OS.



Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies?

RAGE, PRAME, and gp75 expression is found with a different frequency in surgically removed lesions and in RCC cell lines, suggesting that a subgroup of RCC patients could be selected for immunotherapeutic strategies that may benefit from immunization against the RAGE-1, gp75, and/or PRAME antigens.

Expression of MAGE genes in renal cell carcinoma.

The results suggest that owing to the high incidence of MAGE gene expression in RCC, a large proportion of patients could be suitable candidates for novel immune therapies involving tumor-specific antigens encoded by MAGE genes.

p53 Pathway in Renal Cell Carcinoma Is Repressed by a Dominant Mechanism

Consistently, p53 inactivation prevailed in the hybrids of RCC cells with the cells possessing fully functional p53, and cells of normal kidney epithelium also caused partial p53 repression in cell fusion experiments, suggesting that RCC-specific p 53 repression may be based on an unknown dominant mechanism also acting in normal kidney tissue.

Cancer/testis‐associated genes: Identification, expression profile, and putative function

Better insights in the function of these genes may shed light on the link between spermatogenesis and tumor growth and could be of use in anti‐tumor therapies.

The cancer/testis genes: review, standardization, and commentary.

A CT gene database was created to standardize CT nomenclature and accumulate relevant data regarding their expression profiles, immunogenicity, function (where known), gene structure and location, and orthologous groups.

Cancer testis antigens – their importance in immunotherapy and in the early detection of cancer

  • A. Suri
  • Biology, Medicine
    Expert opinion on biological therapy
  • 2006
The development of successful immunotherapeutic strategies requires the identification and characterisation of immunogenic cancer antigens that will be recognised by the host immune system, leading

Protein Expression Profiles in Renal Cell Carcinoma: Staging, Prognosis, and Patient Selection for Clinical Trials

The protein expression profiles in RCC are reviewed and their association with pathobiology, prognosis, and response to treatment as well as their role in serving as potential molecular targets for therapy of RCC is reviewed.

Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens.

Investigation of a broad spectrum of normal and malignant tissues revealed expression of SCP-1 transcripts and antigen selectively in a variety of neoplastic tissues and tumor cell lines, suggesting that the functional role of other CTA might also relate to meiosis.